Clinical Trial Update: A Long Term Safety Study With Atrasentan [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes the completion of a long-term safety study of atrasentan in prostate cancer (adenocarcinoma) across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: Abbott | Conditions: Prostate Cancer, Adenocarcinoma | Phase 2, Phase 3 | Status: COMPLETED